Stock analysts at Evercore ISI started coverage on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a note issued to investors on Wednesday, The Fly reports. The brokerage set a $137.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s price objective suggests a potential upside of 0.33% from the company’s previous close.

ALXN has been the subject of several other research reports. BMO Capital Markets reaffirmed an “outperform” rating and issued a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 18th. Raymond James Financial, Inc. reaffirmed a “strong-buy” rating and issued a $176.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 9th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $142.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday, June 9th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Five investment analysts have rated the stock with a hold rating, twenty have given a buy rating and two have given a strong buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $156.13.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded up 0.99% during trading on Wednesday, hitting $136.55. 1,169,095 shares of the company’s stock were exchanged. The stock has a market cap of $30.48 billion, a P/E ratio of 59.22 and a beta of 1.41. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $145.41. The firm has a 50-day moving average price of $129.88 and a 200-day moving average price of $122.91.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. During the same quarter in the prior year, the company earned $1.13 EPS. The company’s revenue was up 21.1% compared to the same quarter last year. Equities research analysts expect that Alexion Pharmaceuticals will post $5.60 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Now Covered by Analysts at Evercore ISI” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/16/alexion-pharmaceuticals-inc-alxn-now-covered-by-analysts-at-evercore-isi.html.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, June 14th. The shares were purchased at an average price of $116.72 per share, for a total transaction of $1,167,200.00. Following the completion of the purchase, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at $4,519,982. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the business’s stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. Insiders bought 2,019,734 shares of company stock worth $235,606,846 in the last quarter. Company insiders own 4.35% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio raised its stake in Alexion Pharmaceuticals by 1.6% in the second quarter. Public Employees Retirement System of Ohio now owns 151,163 shares of the biopharmaceutical company’s stock worth $18,392,000 after buying an additional 2,394 shares during the last quarter. Wealthsource Partners LLC raised its stake in Alexion Pharmaceuticals by 4.4% in the second quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 126 shares during the last quarter. National Asset Management Inc. raised its stake in Alexion Pharmaceuticals by 5.1% in the second quarter. National Asset Management Inc. now owns 3,345 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 162 shares during the last quarter. Asymmetry Capital Management L.P. acquired a new stake in Alexion Pharmaceuticals during the second quarter worth $1,486,000. Finally, Piedmont Investment Advisors LLC raised its stake in Alexion Pharmaceuticals by 1.0% in the second quarter. Piedmont Investment Advisors LLC now owns 46,533 shares of the biopharmaceutical company’s stock worth $5,662,000 after buying an additional 446 shares during the last quarter. Hedge funds and other institutional investors own 90.74% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

The Fly

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.